Quantcast

Latest Antiretroviral drug Stories

2014-07-03 10:51:21

American Society for Microbiology A novel intravaginal ring implanted with anti-retroviral drug tablets, or pods, demonstrated sustained and controlled drug release and safety over 28 days, according to a paper published ahead of print in Antimicrobial Agents and Chemotherapy. The ring, designed to prevent transmission of HIV, was tested in pig-tailed macaque monkeys, and is engineered to be inexpensive, all the better for use in developing countries, says corresponding author Marc Baum....

2014-07-03 10:47:18

University of Pennsylvania School of Medicine Less than 10 percent of people infected with hepatitis C are cured A new meta-analysis published online in PLOS ONE by infectious disease and epidemiology specialists from the Perelman School of Medicine at the University of Pennsylvania highlights significant gaps in hepatitis C care that will prove useful as the U.S. health care system continues to see an influx of patients with the disease because of improved screening efforts and new,...

2014-07-02 11:04:45

Bulletin of the World Health Organization Efficiency and costs in core HIV services Millions of people in need would benefit from HIV services in developing countries that are moving towards universal health coverage if these services were run more efficiently and integrated better into their health systems. According to a study published in the Bulletin of the World Health Organization today, scaling up HIV services can achieve substantially lower unit-costs per patient, while...

2014-07-01 10:07:43

University of Pennsylvania School of Medicine Lack of clinical trial data, guidelines on HIV patients with cancer may contribute to health disparity HIV-infected people diagnosed with cancer are two to four times more likely to go untreated for their cancer compared to uninfected cancer patients, according to a new, large retrospective study from researchers in Penn Medicine's Abramson Cancer Center and the National Cancer Institute (NCI) published online ahead of print in the Journal...

2014-06-28 09:23:51

University of Pittsburgh Schools of the Health Sciences While bringing new drugs to market is important for increasing life expectancy in younger people with HIV, lowering the toxicity of those drugs may have an even greater health impact on all HIV patients, a University of Pittsburgh Graduate School of Public Health analysis reveals. The research, supported by the National Science Foundation (NSF) and National Institutes of Health (NIH), and published June 25 in the journal PLOS ONE,...

2014-06-24 08:32:27

OAKLAND, Calif., June 24, 2014 /PRNewswire/ -- A 15-year study found that HIV-positive individuals had a 40 percent increased risk of ischemic stroke, however stroke rates were nearly the same for HIV-positive individuals with high CD4 cell counts as for HIV-negative subjects. http://photos.prnewswire.com/prnvar/20130718/SF49717LOGO The study, published recently in AIDS, the official journal of the International AIDS Society, covered the years 1996 through 2011 and included nearly...

2014-06-12 08:28:17

Agreement is ViiV Healthcare's first external collaboration for development of a two drug single-tablet combining dolutegravir and rilpivirine LONDON, June 12, 2014 /PRNewswire/ -- ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland Ltd (Janssen) for the development and commercialisation of a single-tablet combining dolutegravir (Tivicay®) and Janssen's non-nucleoside reverse transcriptase inhibitor rilpivirine (Edurant®([1])). This...

2014-06-12 08:28:09

CORK, Ireland, June 12, 2014 /PRNewswire/ -- Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT(R)) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY(R)) as the sole active ingredients for the maintenance treatment of people living with Human...

2014-06-10 08:29:37

Key findings point to significant differences between treated and untreated people living with HIV RESEARCH TRIANGLE PARK, N.C., June 10, 2014 /PRNewswire/ -- ViiV Healthcare today announced new survey data that provide important insights that may help explain why HIV treatment rates remain low in the United States. Findings from the online survey, conducted by Harris Interactive on behalf of ViiV Healthcare in 2013, reveal gaps in knowledge about HIV and its treatment among diagnosed but...

2014-05-30 08:24:46

First Clinical Application of Genome Editing Technology in Hematopoietic Stem/Progenitor Cells RICHMOND, Calif., May 30, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that the California Institute for Regenerative Medicine (CIRM) has granted a $5.6 million Strategic Partnership Award to fund clinical studies at City of Hope to develop a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of Sangamo's zinc finger nuclease (ZFN)...


Latest Antiretroviral drug Reference Libraries

0_a4499f7c8759b5cbe79bad5eca319070
2011-01-26 14:08:59

Human immunodeficiency virus (HIV), a lentivirus, causes acquired immunodeficiency syndrome (AIDS) which is a condition in humans were the immune system begins to fail, leading to life-threatening opportunistic infections. Infection is transferred through bodily fluids where HIV is present as both free virus particles and within infected immune cells. The four most common routes of infection are unsafe sex, contaminated needles, breast milk, and transmission from an infected mother to her...

More Articles (1 articles) »
Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'